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ABSTRACT
CDC25 phosphatases are important regulators of the cell cycle and represent 
promising targets for anticancer drug discovery. We recently identified NSC 119915 
as a new quinonoid CDC25 inhibitor with potent anticancer activity. In order to 
discover more active analogs of NSC 119915, we performed a range of ligand-
based chemoinformatic methods against the full ZINC drug-like subset and the 
NCI lead-like set. Nine compounds (3, 5–9, 21, 24, and 25) were identified with Ki 
values for CDC25A, -B and -C ranging from 0.01 to 4.4 μM. One of these analogs, 
7, showed a high antiproliferative effect on human melanoma cell lines, A2058 
and SAN. Compound 7 arrested melanoma cells in G2/M, causing a reduction of 
the protein levels of CDC25A and, more consistently, of CDC25C. Furthermore, an 
intrinsic apoptotic pathway was induced, which was mediated by ROS, because 
it was reverted in the presence of antioxidant N-acetyl-cysteine (NAC). Finally, 7 
decreased the protein levels of phosphorylated Akt and increased those of p53, thus 
contributing to the regulation of chemosensitivity through the control of downstream 
Akt pathways in melanoma cells. Taken together, our data emphasize that CDC25 
could be considered as a possible oncotarget in melanoma cells and that compound 
7 is a small molecule CDC25 inhibitor that merits to be further evaluated as a 
chemotherapeutic agent for melanoma, likely in combination with other therapeutic 
compounds.
INTRODUCTION
Cell division cycle 25 proteins (CDC25s) are 
dual-specificity phosphatases (DSPs), acting as key 
regulators of the cell cycle. Indeed, CDC25 controls 
the activity of cyclin-dependent kinases (CDKs), by 
removing inhibitory phosphates from tyrosine and 
threonine residues on the phosphate binding loop 
[1–2]. Regulation of protein levels and activity of 
CDC25 facilitates the orderly progression through the 
cell cycle; furthermore, these enzymes play an important 
role as checkpoint regulators for handling DNA damage 
caused by UV light, ionizing irradiation, or chemicals. 
Therefore, the misregulation of CDC25s could be pivotal 
for causing genomic instability. In humans, CDC25 
belongs to a multigene family consisting of three forms: 
CDC25A, -B, and -C [3]. CDC25A plays an extensive 
role in assisting both G1/S and G2/M progression, by 
dephosphorylating CDK4-Cyclin D [4] and CDK6-
Cyclin D complexes [5], as well as CDK1-Cyclin 
B, CDK2-Cyclin A and CDK2-Cyclin E complexes 
[6–7]. CDC25B is responsible for the initial activation 
of CDK1-Cyclin B complex at the centrosome during 
the G2/M transition, which is then followed by a 
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complete activation of CDK1-Cyclin B complexes by 
CDC25C in the nucleus at the onset of mitosis [8]. 
CDC25B is also able to dephosphorylate and activate 
CDK2-Cyclin A and CDK2-Cyclin E complexes [9–
10]. CDC25C is present in each cell cycle phase and 
regulates the G2/M transition, by targeting CDK1-
Cyclin B complex [11–12]. However, evidence was 
presented that all CDC25 forms can regulate both 
G1/S and G2/M transitions [13]. In order to assure 
a controlled progression through each cell cycle 
phase and thus maintain the genomic integrity, a 
tight regulation of CDC25 phosphatases activity 
is needed, both in unperturbed cell cycle and in 
response to DNA damage checkpoints. This regulation 
depends upon post-translational mechanisms such 
as phosphorylations, sub-cellular relocalization and 
proteasome-mediated degradation [14], together 
with p53-dependent transcriptional repression of the 
three CDC25 phosphatases [15–16]. Misregulation of 
CDC25s has been shown to cause unscheduled entry 
into mitosis, spontaneous mutagenesis and sensitisation 
to DNA damaging agents [17–18]. Further roles have 
been proposed for these phosphatases in diverse areas, 
such as centrosome amplification [19] and steroid 
receptor coactivation [20]. Overexpression of CDC25A, 
CDC25B or both was reported in a wide variety of 
human malignancies including breast, thyroid, laryngeal, 
esophageal, gastric, hepatocellular, ovarian, endometrial, 
prostate, and colorectal, non-Hodgkin lymphomas 
as well as in gliomas, neuroblastoma and melanoma 
[8] and was commonly associated with both tumor 
aggressiveness and poor prognosis [21]. With regard to 
CDC25C, only a few studies showed an overexpression 
of this form in cancers [22–23]. However, growing 
evidence suggests that the overexpression of CDC25C 
could be underrated because of the non-consideration of 
its alternative splicing [21, 24]. In the complex, all these 
observations indicate that CDC25s are promising targets 
for the development of anti-cancer drugs.
Over the past few years, several synthetic and 
natural molecules with different structural features 
targeting CDC25 activity have been reported. Reviews 
by Lavecchia et al. provide a comprehensive overview 
of the current discovery of CDC25 inhibitors [25–27]. 
Most of the known CDC25 inhibitors belong to various 
chemical classes including phosphate bioisosteres, 
electrophilic entities, and quinone-based structures. 
It is thought that there are three possible mechanisms 
through which these molecules inhibit CDC25s 
and other phosphatases, i.e. reversible inhibition 
through binding to the active site of CDC25s [28–29], 
irreversible inhibition of CDC25s through a direct 
binding with the inhibitor [30–31], or oxidation of 
the critical cysteine residue in the catalytic domain 
(CX5R) by reactive oxygen species (ROS) generated in 
cultured cells treated with quinone derivatives [32–33]. 
This latter mechanism could be consistent with the 
non-selective inhibition of CDC25 phosphatases by 
quinone-type inhibitors. Moreover, ROS may oxidize 
other phosphatases, as well as unrelated cysteine-based 
enzymes, and therefore quinone-containing agents could 
potentially trigger several unrelated events in cells. To 
date, many of the most potent CDC25 inhibitors are 
quinone-containing compounds, which inhibit all three 
forms of CDC25 in an unselective manner. Among 
these, NSC 95397 [28], NSC 663284 [30], BN82685 
[34] and IRC-083864 [35] are representative potent 
inhibitors (Figure 1).
We have previously reported the discovery of a new 
quinonoid CDC25 inhibitor (NSC 119915 in Figure 1) 
by means of a structure-based high-throughput virtual 
screening [36]. This compound displayed irreversible 
Figure 1: Known quinone-containing CDC25 Inhibitors. 
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inhibition kinetics with in vitro Ki values for CDC25A and 
-B of 0.07 and 0.08 μM, respectively; furthermore, NSC 
119915 generated an increase of the intracellular ROS 
level, arrested cells in the G0/G1 and G2/M phases of the 
cell cycle, and significantly inhibited the growth of human 
MCF-7 breast, PC-3 prostate, and K562 leukaemia cancer 
cell lines.
It is known that melanoma, one of the most 
aggressive tumors, is very refractory to any conventional 
therapies. Therefore, a great effort has been devoted to 
discover new molecules helpful in the treatment of this 
cancer acting through the modulation of key pathways of 
cell proliferation. CDK2 and CDK6, cyclins D1, E, and D3 
and phosphatase CDC25A are consistently overexpressed 
in metastatic melanomas compared with nevus tissue 
[37–38]. Hence, the potent inhibition displayed by 
the compound NSC 119915 towards CDC25 could be 
suggestive of its possible activity even in melanoma, 
and therefore it was judged as an appropriate choice for 
studying its activity against melanoma cells.
In this study, we described the use of 
chemoinformatic and virtual screening (VS) approaches 
against the full ZINC drug-like subset [39–40] and 
the NCI (National Cancer Institute) lead-like set to 
potentially identify more active analogs of our lead 
compound NSC 119915 and to expand our understanding 
of structure-activity relationships (SARs). Our strategy, 
based on atom connectivity similarity and substructure 
searches, led to the identification of twenty-five analogs 
of NSC 119915. Among them, nine compounds, that 
share a same 6-xanthone chemical motif (3, 5–9, 21, 24, 
and 25), showed an in vitro inhibitory activity towards 
CDC25A, -B and -C, comparable with that exerted by 
NSC 119915. The effect of these compounds was also 
evaluated in a cellular context, using the melanoma cell 
lines A2058 and SAN. The data showed that compound 
7 was by far the most effective one in the inhibition of 
cell proliferation, as emerging from the cytotoxicity 
tests. Furthermore, compound 7 affected the cell cycle 
progression, modulated the CDC25 protein levels 
and triggered the cell death, by inducing an apoptotic 
program, as evaluated through different markers. In 
addition, 7 produced an alteration of the cellular redox 
state and caused a mitochondrial dysfunction, likely 
associated to a modulation of the Akt pathway.
RESULTS
Compound selection using chemoinformatics
As the primary goal of this work was to identify 
novel structural analogs with increased CDC25 inhibitory 
potency of lead compound NSC 119915, we applied 
different chemoinformatic approaches [41–42] against 
both the ZINC drug-like library and the NCI lead-like 
set. The general workflow of the multiple ligand-based 
chemoinformatic approaches implemented in this work is 
presented in Figure 2.
The first five VS approaches employed molecular 
fingerprints, which are binary vectors encoding the 
presence, or absence, of substructural fragments within 
the molecule and have been successful in recognizing 
similar molecules in large databases [43]. We employed 
ECFP2, ECFP4, FCFP2, FCFP4, and FCFP6 to identify 
close active analogs to our lead NSC 119915, using the 
Tanimoto coefficient as similarity measure. To enhance the 
probability of finding 50% of all possible actives, we used 
the threshold values suggested by Muchmore et al. [44] 
So, a Tanimoto threshold of 0.52 for ECFP2 allowed the 
selection of 13 compounds, whereas a Tanimoto threshold 
of 0.43 for ECFP4 gave 12 compounds. For FCFP2, a 
Tanimoto threshold of 0.75 provided 16 compounds; for 
FCFP4, a Tanimoto threshold of 0.60 gave 5 compounds; 
and for FCFP6, a Tanimoto coefficient of 0.45 highlighted 
8 compounds. The sixth method utilized was that of the 
substructure search using the core of lead NSC 119915. 
By definition, a substructure search identifies molecules 
that contain a defined molecular fragment, that is, a certain 
substructure. Of course, such a search will not lead to new 
scaffolds, but will allow the finding of close analogs and 
possible variations in the decoration of known molecule 
classes. The substructure search identified 137 scaffold 
isosteres of our lead core structure.
The results of the six VS techniques were combined, 
and a significant number of identical compounds were 
found; this overall strategy led to a final total of 126 
unique compounds, that were predicted by one or 
more methods to be similar in some way to our active 
compound. As we were not able to screen this number of 
compounds by in vitro assays, we selected the top-ranked 
25 compounds that were purchased or requested from 
the NCI Developmental Therapeutics Program (DTP) 
(Table 1). Our decision to select compounds from the top-
ranked compounds was to ensure testing of any highly 
similar (and therefore likely to be active) compounds.
Effect of the close analogs of NSC 119915 on the 
phosphatase activity of purified recombinant 
forms of CDC25
A preliminary screening of the inhibition properties 
of the close analogs of NSC 119915 was carried out by a 
fluorimetric assay, that measured the residual phosphatase 
activity of a recombinant form of CDC25B in the presence 
of the selected compounds. The solutions of NSC 119915 
and of its structural analogs were carefully monitored 
to avoid artifacts due to precipitation or agglomeration 
of the compounds. Among the twenty-five structures 
identified from the multiple ligand-based chemoinformatic 
approach, eight compounds (2, 10, 12–14, and 16–18) were 
excluded from the analysis, because endowed with a strong 
fluorescent signal, which interfered with the emission 
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wavelength of the synthetic substrate 3-O-methylfluorescein 
phosphate (OMFP) used in the fluorimetric assay. The 
inhibition of the phosphatase activity of CDC25B by the 
remaining seventeen analogs was evaluated in the presence 
of two different concentrations of these compounds 
(Table 2). The data indicated that compounds 5–9, 21, 24, 
and 25, that contain a 6-xanthone chemical motif, exerted 
a concentration-dependent inhibition of the CDC25B 
phosphatase activity, with a percentage of inhibition 
comparable to that exhibited by compound NSC 119915 
(Supplementary Figure S1). In contrast, compounds 1, 3, 
4, 11, 15, 19, 20, 22, and 23 caused a measurable inhibition 
of the phosphatase activity, only when added at the highest 
concentration. For this reason, only one of these latter 
compounds, i.e. 3, was included in the following analysis.
The inhibition properties of the effective inhibitors 
were better investigated through the kinetic measurement 
of their Ki values. For instance, Figure 3 shows the 
kinetic evaluation of the inhibitory effect of compound 
7 on the three CDC25 forms, as representative of the 
inhibition mechanism exerted by these compounds; 
indeed, a similar behaviour was observed with the other 
6-xanthone derivatives, thus allowing the measurement of 
the corresponding Ki values.
As shown in Table 3, the low Ki values confirmed 
that these compounds possessed an effective inhibition 
towards CDC25A, -B or -C. Indeed, the measured Ki 
values obtained for the 6-xanthone derivatives were 
similar to that determined for NSC 119915 and all 
comprised in relatively small intervals; in particular, 
the Ki towards CDC25A ranged between 0.01 and 0.80 
μM, and the corresponding intervals for CDC25B 
and CDC25C were 0.12–2.4 μM and 0.30–4.4 μM, 
respectively. Furthermore, when considering the inhibition 
potency of each compound towards the different CDC25 
phosphatases, a similar efficacy was observed, because 
no great differences emerged from the comparison of the 
respective Ki values. However, among the three forms, 
CDC25A showed a slightly higher sensitivity towards 
the inhibitors, whereas CDC25C had a moderately 
lower responsiveness. Concerning the mechanism of 
inhibition, the kinetic measurements showed that the 
tested compounds had a behaviour similar to that already 
reported for NSC 119915 [36]. In particular, in the 
presence of the inhibitors the K
M
 value for the substrate 
OMFP was not essentially modified, whereas the V
max
 of 
phosphatase activity was significantly reduced. Therefore, 
the tested analogs of NSC 119915 were noncompetitive 
Figure 2: Flow chart of the multiple ligand-based chemoinformatic strategy implemented in this work. 
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Table 1: Compounds identified by multiple ligand-based chemoinformatic protocol
Cpd Code R1 R2 R3 R4 R5 Cpd Code R1 R2 R3 R4 R5
1 NSC158113 CH
3
H H H H 14 NSC4202 H I I H
2 ZINC 04015433 CH
3
OH H H OH 15 NSC4905 I I I I
3 NSC158115 COOH H H H H 16 ZINC 04409973 H Cl Cl H
4 NSC158112 CH2CH2COOH H H H H 17 ZINC 04352921 H Br Br H
5 NSC119894 CH=CHCOOH H H H H 18 NSC2087 Br Br Br Br
6 NSC119911 CH=CHCOOH H OH OH H 19 ZINC04261930 NO2 Br Br NO2
7 NSC119892 H H H H 20 ZINC03861600 H OH OH H
8 NSC119910 H OH OH H 21 NSC119893 H OH OH H
9 ZINC 03860685 OH H H OH 22 ZINC04822213 OH H H OH
10 ZINC 13597410 OH H H OH 23 ZINC04582279 H H H H
11 ZINC05030632 H H H H 24 NSC 119912 H OH OH H
12 NSC 119888 H H H H 25 NSC 119916 H OH OH H
13 ZINC 05030658 H H H H
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inhibitors of CDC25 and probably acted in an irreversible 
manner.
Evaluation of CDC25 inhibitors on cell growth 
rate of A2058 and SAN melanoma cells
In a previous work we found a strong 
antiproliferative action of NSC 119915 on some cancer 
cell lines [36]. Here, we investigated the effects of NSC 
119915 and its selected 6-xanthone analogs on the growth 
rate of two melanoma cell lines, A2058 and SAN. In 
particular, the effect of the inhibitors was evaluated 
after different times of treatment with 25, 50 or 100 μM 
NSC 119915 or its analogs 3, 5–9, 21, and 24–25. The 
minimum concentration of inhibitor that caused an evident 
cytotoxic activity was 100 μM, as demonstrated for cpd 7 
Table 2: Residual phosphatase activity of CDC25B in the presence of compound NSC 119915 or 
its 6-xanthone analogs
Cpd CDC25B residual activity (%) in the presence of [inhibitor]
0.2 μM 1 μM
1 76 9
3 85 62
4 90 28
5 12 2
6 14 2
7 44 1
8 10 1
9 9 0
11 89 44
15 79 18
19 86 70
20 91 24
21 13 1
22 80 0
23 80 14
24 22 3
25 24 1
NSC 119915 38 2
Figure 3: Effect of compound 7 on the Lineweaver-Burk plots of the A. CDC25A B. CDC25B and C. CDC25C phosphatase 
activity. The phosphatase activity was measured through the rate of OMFP hydrolysis as described in the Materials and Methods. The 
activity was determined either in the absence (empty circles in A., B. and C.) or in the presence of the following concentrations of compound 
7: 0.5 μM (filled triangles in A.), 0.25 μM or 0.5 μM (filled triangles or filled circles, respectively, in B.), 1 μM (filled triangles in C.).
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in Supplementary Figure S2; therefore, this concentration 
was almost thoroughly used in the following experiments. 
Figure 4 shows the cell growth rate of A2058 and SAN 
cells after 48-h treatment in the presence of 100 μM of 
the different compounds. As shown in Figure 4A, only 
compound 7 caused a significant reduction of the cell 
growth rate of A2058, whereas the other derivatives, as 
well as NSC 119915, were quite ineffective or caused a 
not significant reduction of cell growth rate. A similar 
behaviour was observed after 72-h incubation; indeed, 
only compound 7 provoked the significant reduction 
of cell growth rate (data not shown). Figure 4B reports 
the effect of the inhibitors in SAN cells; in this case, 
three compounds, i.e. 6, 7 and 24, caused a significant 
reduction of cell growth rate after 48-h treatment. When 
the treatment was prolonged up to 72 h, also compound 
NSC 119915 exerted a significant reduction of cell growth 
rate (not shown). In conclusion, compound 7 could be 
representative of the effect of this group of molecules in 
melanoma cells, because of the significant cytotoxicity 
observed in both cell lines.
Effect of compound 7 on cell cycle progression 
and apoptosis
As CDC25 phosphatases are key cell cycle 
regulators, the effect of 7 on cell cycle progression was 
investigated in detail. To this aim, asynchronously growing 
A2058 and SAN cells were treated at different times with 
100 μM compound 7, and then cell cycle analysis was 
cytofluorimetrically monitored after propidium iodide 
(PI) incorporation. Figure 5 shows the time-dependent 
distribution of the cell cycle in its different phases of 
A2058 cells. After 16-h incubation with vehicle alone, cells 
were mainly and almost equally distributed in G0/G1 and 
G2/M phases (the ratio between them being 0.96), whereas 
the cellular population in the S phase was essentially 
undetectable. On the other hand, after 16-h treatment with 
7, a significant reduction of cells in G0/G1 phase was 
evident, accompanied by a significant improvement of 
the G2/M cell arrest (Figure 5A); in particular, the ratio 
between G0/G1 and G2/M decreased to 0.38 (p < 0.05). 
A similar behaviour was observed if the incubation was 
prolonged up to 24 h (Figure 5B); in this case the ratio 
between G0/G1 and G2/M decreased from 1.23 (untreated 
cells) to 0.45 (treated cells; p < 0.01). A similar general 
picture emerged from the effect of compound 7 on cell 
cycle progression of SAN cells (Supplementary Figure 
S3). In spite of some differences in the relative cell phase 
distribution, also in these melanoma cells compound 7 
caused an increase of cell distribution in the G2/M phase 
after 16- and 24-h treatment.
It is known that CDC25 phosphatases are crucial 
regulators of cell cycle progression, and the previous 
in vitro results indicated that compound 7 was a potent 
inhibitor of CDC25. To better investigate the effect of 
this inhibitor at the molecular level, we evaluated if the 
treatment of A2058 cells with 7 affected also the protein 
levels of the three CDC25 forms. The Western blotting 
analysis reported in Figure 6 shows that compound 7 
provoked an early reduction of the CDC25A protein 
levels up to 4 h compared to untreated cells; this reduction 
disappeared under prolonged incubation times. The 
treatment of melanoma cells with compound 7 also caused 
a reduction of the CDC25C protein levels, although with 
a late kinetics. In particular, a progressive and significant 
reduction of CDC25C protein levels was observed, starting 
from 4 h and continuing up to 16 h. On the other hand, the 
protein levels of CDC25B were unaffected by treatment 
of A2058 cells with 7 up to 16 h. An earlier decrease of 
Table 3: Ki values of compound NSC 119915 or its 6-xanthone analogs towards CDC25-A, -B and 
-C phosphatases
Cpd Ki (μM)
CDC25A CDC25B CDC25C
3 0.28 ± 0.09 2.4 ± 0.39 4.4 ± 0.62
5 0.38 ± 0.12 0.12 ± 0.05 0.39 ± 0.15
6 0.10 ± 0.03 1.1 ± 0.37 1.0 ± 0.41
7 0.65 ± 0.04 0.78 ± 0.03 3.1 ± 0.22
8 0.17 ± 0.07 0.19 ± 0.08 0.30 ± 0.12
9 0.80 ± 0.31 0.44 ± 0.2 1.5 ± 0.48
21 0.14 ± 0.06 0.14 ± 0.05 0.63 ± 0.14
24 0.01 ± 0.005 0.3 ± 0.08 0.40 ± 0.11
25 0.40 ± 0.15 1.1 ± 0.4 0.96 ± 0.38
NSC 119915 0.34 ± 0.12 0.10 ± 0.04 0.24 ± 0.13
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CDC25C protein levels was observed even in SAN cells 
treated with compound 7 (Supplementary Figure S4). 
These overall results suggest that the modulation of the 
CDC25 protein levels induced by 7, in particular of the -A 
and more evidently of the -C form, could be related to the 
arrest of melanoma cells in G2/M observed in the presence 
of this inhibitor.
The effect of 7 on cell growth and cycle progression 
could suggest the beginning of a cell death program, a 
hypothesis investigated through various methodological 
approaches. PI incorporation followed by flow cytometric 
analysis was used to detect the effect of 7 on the number 
of nuclei with a sub-diploid content, a typical hallmark 
of apoptosis. A time-dependent increase of apoptosis was 
evident in both A2058 and SAN cells and in particular, the 
effect of 7 on cell death program was already evident after 
24-h treatment (Figure 7). In A2058 cells the increase of 
apoptosis became significant at 48 h, and continued at least 
up to 72-h incubation (Figure 7A). In SAN cells a similar 
behaviour was observed and the increase of apoptosis was 
significant even at 24-h treatment (Figure 7B). To further 
investigate on the capacity of 7 to induce apoptosis, the 
enzymatic activity of caspase-3, the final effector of 
apoptotic program, was monitored. Indeed, this inhibitor 
provoked a significant increase of the enzymatic activity 
of caspase-3 in both A2058 (Figure 7C) and SAN cells 
(Figure 7D).
To confirm that the pro-apoptotic effect of 7 was 
caspase-mediated, the 48-h treatment of A2058 and 
SAN cells with compound 7 was also carried out in the 
presence of an irreversible pan-caspase inhibitor, such 
as Z-VAD-FMK. The level of apoptosis caused by 7 was 
significantly decreased in the presence of this inhibitor 
in both A2058 (Figure 8A) and SAN cells (Figure 8B), 
thus demonstrating that the pro-apoptotic effect of 7 was 
mainly caspase-dependent. Taken together, all these data 
support the hypothesis that cell cycle arrest in G2/M phase 
caused by 7 could evolve in an apoptotic process.
Effect of compound 7 on ROS generation and 
mitochondrial membrane potential
The high redox reactivity of quinonoid molecules, 
like compound 7, could greatly perturb the intracellular 
redox state. Indeed, a time-dependent increase of the 
ROS level was observed upon treatment of A2058 cells 
with 7 and this enhancement became significant after 
4-h (Figure 9A). A similar behaviour was observed also 
in SAN cells (Supplementary Figure S5A). The oxidant 
effect of 7 was also evaluated after cell pre-treatment with 
two antioxidant molecules, such as N-acetyl-cysteine 
(NAC) and the specific inhibitor of NADPH oxidase, 
apocynin. To this aim, A2058 and SAN cells were pre-
incubated for 1 h with 10 mM NAC or 45 min with 0.5 
Figure 4: Effect of NSC 119915 and its close analogs on cell growth rate of melanoma cells. A. A2058 and B. SAN cells were 
incubated for 48 h with 0.5% DMSO as a vehicle control or 100 μM of each of the indicated compounds. The cell growth rate is reported as 
arbitrary units (a.u.). Data from four independent experiments are reported as the means ± SE. *p < 0.05 and **p < 0.01 compared to control cells.
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mM apocynin and then treated for 4 h with 100 μM 
compound 7. The increase of ROS level was prevented by 
the NAC treatment in both A2058 (Figure 9B) and SAN 
cells (Supplementary Figure S5B). In contrast, apocynin 
did not prevent the increase of ROS level caused by 7 in 
both melanoma cell lines, even though this antioxidant 
raised the basal intracellular redox state of untreated SAN 
cells. The cytotoxic activity of 7 could be mediated by the 
observed increase of ROS level. Under this concern, pre-
incubation of A2058 and SAN cells with an anti-oxidant 
molecule could prevent the apoptotic process; indeed, 
the apoptosis was in a great part reverted by the cellular 
pre-treatment with NAC (Figure 9C and Supplementary 
Figure S5C). Taken together, all these findings suggest that 
7 altered the intracellular redox state of melanoma cells, 
thus mediating the observed cytotoxicity.
Mitochondria represent the primary source of ROS, 
as well the target of ROS action, and therefore, compound 
7 could affect their functionality in melanoma cells. A 
decrease of the fluorescent signal, corresponding to a 
reduction of the mitochondrial membrane potential, was 
already evident after 24-h treatment of A2058 cells with 
7 and then continued at least up to 72 h (Figure 10A). 
Proteins belonging to the B-cell lymphoma-2 (Bcl-2) 
family are involved in the modulation of the mitochondrial 
functionality [45–46]. Therefore, we have evaluated the 
levels of the anti-apoptotic protein Bcl-2, as well as that 
of the pro-apoptotic Bcl-2-associated X protein (Bax), 
after incubation with 7 (Figure 10B). In A2058 cells the 
incubation with the inhibitor caused a clear reduction 
of the Bcl-2 level after 8-h treatment, and this decrease 
was still evident after 16 h; on the other hand, a clear 
increase of Bax was observed after 16-h incubation with 
7 (Figure 10C). The densitometric analysis also included 
the measurement of the Bcl-2/Bax ratio, and its significant 
reduction observed after 8 and 16 h represents a better 
tool to reveal the regulation of the apoptotic process. To 
further investigate the occurrence of a mitochondrial-
Figure 5: Effect of compound 7 on the distribution of cell cycle phases of A2058 cells. The determination of cells in the different 
phases was evaluated after A. 16 h or B. 24 h from treatment with 0.5% DMSO or 100 μM compound 7, as described in the Materials and 
Methods. Histograms, which show the cell percentage among the various phases, were obtained from triplicate experiments and reported as the 
means ± SE. *p < 0.05 and **p < 0.01 compared to control cells. Vehicle alone, open bars; compound 7, black bars.
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mediated apoptosis induced by 7, the caspase-9 activity 
was assayed. A clear increase of caspase-9 activity was 
measured in A2058 cells after 24-h incubation with 7 
(Figure 10D). The effect of compound 7 was investigated 
also in SAN cells and the overall results were similar to 
those observed in A2058 (Supplementary Figure S6). 
In particular, in SAN cells both levels of Bcl-2 and Bax 
were reduced by the inhibitor treatment; however, the 
most crucial parameter for monitoring the pro-apoptotic 
effect of 7, the Bcl-2/Bax ratio, significantly decreased 
in the presence of 7, because of the greater reduction of 
Bcl-2 compared to that of Bax. All these data indicate that 
the increase of ROS levels associated to an alteration of 
typical mitochondrial markers could contribute or mediate 
the cytotoxic effect exerted by 7 in melanoma cells.
Effect of compound 7 on Akt activation and p53 
protein levels
The molecular mechanisms that regulate the cytotoxic 
potential of 7 in melanoma cells were further investigated 
through the evaluation of the activation state of protein kinase 
B (pAkt), one of the key proteins involved in the control and 
regulation of cell survival [47–48]. To this aim, the protein 
Figure 6: Effect of compound 7 on CDC25A, B and C protein levels. Total protein extracts from A2058 cells, incubated 
with 0.5% DMSO (open bars) or 100 μM compound 7 (black bars) for 2, 4, 8 or 16 h, were analyzed by Western blotting. GAPDH was 
used as loading control. The doublets observed in the immunoblots detecting CDC25A or CDC25C were due to the common presence 
of multiple isoforms of these proteins. Densitometric analysis is shown in the lower panel. Data from triplicate experiments were 
reported as the means ± SE. *p < 0.05, **p < 0.01, ***p < 0.001, compared to control cells. Other details as described in the Materials 
and Methods.
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levels of pAkt have been analyzed after 2- and 4-h incubation 
of A2058 cells with 7. As shown in Figure 11A, the inhibitor 
caused an early reduction of the protein level of pAkt with 
respect to total Akt; indeed, this decrease was already evident 
after 2-h and remained detectable until 4-h incubation. An 
early reduction of Akt activation was observed also in SAN 
cells (Supplementary Figure S7). It is known that Akt regulates 
the process of cell survival by phosphorylating different 
substrates, directly or indirectly involved in the apoptotic 
program [49]. One of these targets is p53, a protein with a 
tumor-suppressor activity that regulates the cell cycle, as well 
as the expression of several genes involved in the apoptosis 
[49]. In particular, Akt negatively regulates the apoptosis, by 
enhancing the degradation of p53 via its phosphorylation, as 
well as by promoting the nuclear localization and binding 
of this factor to human murine double-minute 2 (MDM2) 
protein, a negative regulator of p53 [49]; therefore, we tested 
if the CDC25 inhibitor 7 affected the protein levels of p53. 
As shown in Figure 11B, the higher level of p53 compared to 
control, already evident after 8-h incubation of A2058 cells 
with compound 7, became significant after 16-h treatment, 
because of the reduction of its basal level in untreated cells. 
Also in SAN cells a time-dependent reduction of the basal 
level of p53 was observed, together with a higher level of this 
protein measured in treated cells after 16-h incubation (not 
shown). We can suggest that the modulation of p53 protein 
levels represents one of the molecular events linked to the 
early decrease of pAkt caused by 7.
Figure 7: Effect of compound 7 on the apoptosis of A2058 and SAN cells. The apoptotic process was evaluated in A2058 
(panels A. and C.) and SAN (panels B. and D.) cells either through the determination of the number of cells with a subdiploid DNA content 
(A. and B.) or by measuring the caspase-3 enzymatic activity (C. and D.). Cells were treated with 0.5% DMSO (open bars) or 100 μM 
compound 7 (black bars) for the indicated incubation times. Apoptosis was expressed as a percentage, whereas caspase-3 activity was 
reported as arbitrary units (a.u.). Data from triplicate experiments were reported as the means ± SE. *p < 0.05, **p < 0.01, ****p < 0.0001, 
compared to control cells. Other details as described in the Materials and Methods.
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DISCUSSION
By combining experimental and computational 
methods, we have identified a set of inhibitors of 
CDC25 phosphatases, which are key elements in the 
control of the cell cycle in eukaryote cells, in normal 
conditions as well as in response to cell damage, and 
whose overexpression is associated to a wide variety 
of cancers [8, 21]. Specifically, we employed a number 
of ligand-based chemoinformatic methods in the 
rational selection of 25 close analogs of our lead NSC 
119915 [36], that were predicted to possess inhibitory 
Figure 8: Effect of Z-VAD-FMK, a pan-caspase inhibitor, on the apoptotic process induced in melanoma cells by 
compound 7. A2058 (panel A.) and SAN (panel B.) cells were treated with 0.5% DMSO or 100 μM compound 7 and incubated in the 
absence or in the presence of 100 μM Z-VAD-FMK; the apoptosis was evaluated after a 48-h incubation through the determination of the 
number of cells with a subdiploid DNA content. Data from triplicate experiments were reported as the means ± SE. **p < 0.01, ***p < 
0.001 and ****p < 0.0001 compared to respective control cells. Other details as described in Materials and Methods.
Figure 9: ROS production and their involvement in the apoptotic process of A2058 cells, as induced by treatment 
with compound 7. A. Time-dependent measurement of ROS production. Cells were incubated with 0.5% DMSO (open bars) or 
100 μM compound 7 (black bars) and then the intracellular ROS level was measured. B. Effect of antioxidant molecules on ROS 
production. The ROS level was also measured in cells untreated or pretreated with NAC or apocynin after a 4-h incubation with 
DMSO or 7. C. Effect of NAC on apoptosis. The PI incorporation was evaluated in cells untreated or pretreated with NAC after a 48-h 
incubation with DMSO or 7. ROS production was expressed as a.u., and apoptosis as a percentage. Data from triplicate experiments 
were reported as the means ± SE. *p < 0.05 and **p < 0.01 compared to control cells. Other details as described in the Materials and 
Methods.
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activity against the CDC25A, -B and -C phosphatases. 
Interestingly, among the 25 candidates, nine compounds 
sharing the same 6-xanthone motif (3, 5–9, 21, 24, and 
25) caused a dose-dependent inhibition of the CDC25B 
phosphatase activity. Kinetic analyses revealed that 
these compounds inhibited the three different CDC25 
proteins in a noncompetitive manner with Ki values 
comparable to those of the lead compound NSC 119915. 
However, among the three forms, CDC25A showed a 
slightly higher sensitivity towards the inhibitors, whereas 
CDC25C had a moderately lower responsiveness.
As CDC25 phosphatases, in combination with 
other cell cycle regulators, have been proved to be of 
determinant significance for melanoma growth and/
Figure 10: Effect of compound 7 on some apoptotic mitochondrial markers in A2058 cells. A. Measurement of the 
mitochondrial membrane depolarization. Cells were treated for the indicated times with 0.5% DMSO (open bars) or 100 μM compound 7 
(black bars). B. Evaluation of Bcl-2 and Bax protein levels. Total protein extracts from A2058 cells, incubated with 0.5% DMSO or 100 μM 
compound 7 for 8 or 16 h, were analyzed by Western blotting. β-actin was used as loading control. C. Densitometric analysis of the Bcl-2 
and Bax protein levels, as well as of the Bcl-2/Bax ratio. D. Determination of the caspase-9 enzymatic activity. Total protein extracts from 
A2058 cells, incubated with 0.5% DMSO (open bars) or 100 μM compound 7 (black bars) for 24 h, were assayed for caspase-9 activity. 
Data from triplicate experiments were reported as the means ± SE. *p < 0.05, **p < 0.01, ****p < 0.0001, compared to control cells. Other 
details as described in the Materials and Methods.
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or transformation [37–38], we evaluated the effects 
of NSC 119915 and its close analogs on the growth 
rate of two melanoma cell lines, A2058 and SAN. 
Compound 7 [2-(6-hydroxy-3-oxo-3H-xanthen-9-
yl)cyclohexanecarboxylic acid] resulted as the only 
common inhibitor of the cell growth rate of both A2058 
and SAN melanoma cells. However, in SAN cells, 
also the analogs 6 [(E)-3-(4,5,6-trihydroxy-3-oxo-
3H-xanthen-9-yl)acrylic acid] and 24 [(1R,3R,4S)-3-
(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl)bicyclo[2.2.1]
hept-5-ene-2-carboxylic acid], as well as in some 
experimental conditions also NSC 119915, caused 
a significant reduction of the cell growth rate. The 
failure of compounds 3, 5, 8, 9, 21 and 25 to inhibit 
cell proliferation despite their potent inhibition of 
all three CDC25 phosphatases could be due to poor 
permeability into cells, chemical instability, unfavourable 
compartmentalization, active metabolism into inactive 
compounds, presence of unidentified binding proteins, 
or a combination of these factors. In conclusion, for its 
common behaviour in both melanoma cell lines, 7 was 
selected as the most promising compound for further 
investigation of its anti-melanoma effects.
CDC25s are fine regulators of the different phases 
of cell cycle. Hence, we checked if the reduction of cell 
growth rate caused by 7 was associated to an alteration 
of cell cycle progression. A significant reduction of the 
G0/G1 phase and an increase of the G2/M phase occurred 
in both melanoma cell lines after 16-h treatment and 
continued up to 24-h. It is known that many cytotoxic 
compounds, as well as various anti-cancer drugs, cause 
DNA damage [50–51]. This event can induce an arrest 
of cell proliferation, thus enabling cells to DNA repair 
in order to prevent cell death. On the other hand, if the 
mechanisms involved in the DNA repair are ineffective 
and the DNA damage is not completely repaired, 
cells can be committed to programmed cell death. As 
CDC25 proteins exert a pivotal role in the regulation 
of cell division cycle [8], their overexpression might 
facilitate checkpoint exit and contribute to neoplastic 
transformation. Hence, CDC25 inhibition, inactivation 
or degradation can amplify the cytotoxic activity of some 
compounds. The treatment of A2058 cells with 7 caused 
a modulation of the CDC25 protein levels. In particular, 
we observed an early and great reduction of CDC25A 
associated to a progressive decrease of CDC25C, that 
continued up to 16 h. These results suggest that the 
observed G2/M arrest of cell cycle in melanoma cells 
could depend on an inhibition of phosphatase activity of 
CDC25 proteins, as well as on a reduction of the protein 
levels of CDC25A and, more consistently, of CDC25C, as 
also observed in SAN cells. This behaviour seems in good 
agreement with the major role played by CDC25C in the 
control of the G2/M progression of cell cycle [52].
The reduction of cell growth rate and the G2/M 
block of cell cycle could evoke the beginning of a cell 
death program. Indeed, compound 7 activated a time-
dependent apoptotic program in melanoma cells, as 
Figure 11: Effect of compound 7 on pAkt and p53 protein levels. A. Evaluation of pAkt protein levels. Total protein extracts from 
A2058 cells, incubated with 0.5% DMSO or 100 μM compound 7 for 2 or 4 h, were analyzed by Western blotting using an antibody raised 
against pAkt (Ser473). Akt was used as loading control. Densitometric analysis shown in the lower panel. B. Evaluation of p53 protein 
levels. Total protein extracts from A2058 cells, incubated with 0.5% DMSO or 100 μM compound 7 for 8 or 16 h, were analyzed by Western 
blotting. GAPDH was used as loading control. Densitometric analysis shown in the lower panel. Data from triplicate experiments were 
reported as the means ± SE. *p < 0.05, ***p < 0.001, compared to control cells. Other details as described in the Materials and Methods.
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revealed by PI incorporation experiments and caspase-3 
activity measurements. Hence, we can infer that the 
apoptosis observed in melanoma cells represents a 
consecutive process to the long cell cycle blockage in 
the G2/M phase.
It is known that quinonoid structures, as those of 
the most active CDC25 inhibitors, are good substrates 
for the beginning of a redox cycle, and that an increased 
ROS level may cause severe damages to the CDC25 
structure [32, 53–54]. Indeed, quinonoid compounds 
exert their inhibitory activity on CDC25 through the 
oxidation of cysteine residues located in the active site 
[33, 36]. On the other hand, the increase of ROS level 
may be deleterious also to other cellular components, thus 
activating various metabolic pathways that control the cell 
cycle. Compound 7 increased the intracellular ROS levels 
in both melanoma cells, and this event was reverted by 
NAC, whereas apocynin, was ineffective. It is known that 
NAC is the precursor of glutathione, the main intracellular 
antioxidant, whereas the target of apocynin is NADPH 
oxidase, the most important ROS producer located on the 
membrane. On the basis of the different effect exerted by 
these two antioxidant molecules, we could speculate that 
the lipophilicity of 7 allows its efficient crossing through 
the cellular membrane, thus affecting the intracellular 
ROS level; however, the presence of some polar groups 
in 7 probably prevents its stable interaction with the 
inter-membrane components, such as NADPH oxidase. 
The finding that also the apoptosis was reduced by NAC 
suggests that the increase of intracellular ROS levels may 
be considered as an early event involved in the signalling 
triggered by compound 7.
The apoptotic machinery is an essential element 
of cell cycle checkpoints and the cytotoxic effects of 
many drugs are mediated in the mitochondrion through 
the activation of an intrinsic apoptotic pathway. Bcl-
2 family members play a role not only in the regulation 
of apoptosis, but also in the control of cell cycle [55]. In 
this work, the observed increase of ROS levels, as well 
as the decrease of the crucial parameter for controlling 
life and death of a cell, i.e. the Bcl-2/Bax ratio, are clear 
markers of an involvement of the mitochondrion in the 
apoptotic program triggered by 7 in our cell systems. 
This hypothesis was further supported by the reduction 
of mitochondrial membrane potential, as well as by the 
increase of caspase-9 activity. Hence, our findings indicate 
that the alteration of the redox state induced by 7 could 
represent an underlying mechanism for the activation of 
the mitochondrial apoptotic pathway in melanoma cells.
Chemoresistance represents a typical hallmark 
of advanced melanomas. It has been reported that 
the aggressive nature of melanoma is related to an 
accumulation of mutations in several key proliferation- 
regulating mechanisms, as well as in apoptosis-controlling 
pathways [56]. Defects in Akt expression occur in a 
significant proportion of malignant melanomas [57]. 
Under this concern, the early reduction of the pAkt protein 
levels caused by 7 was very interesting, because it has 
been demonstrated that CDC25B mediates the activation 
of Akt, probably through a dephosphorylation mechanism 
of specific protein kinases [58–59]. A key molecule 
involved in the regulation of cell cycle and apoptosis 
pathway is p53. Frequently, in melanoma this protein is 
not mutated, but its impaired functions depend on high 
levels of the phosphorylated form of MDM2, a typical 
inhibitor of p53 [60]. The time-dependent decrease of the 
basal level of p53 observed in both melanoma cells, and 
its higher level measured in treated cells mainly after a late 
incubation with 7, suggest that this compound could affect 
the p53 protein stability. Indeed, higher levels of p53 in 
treated compared to untreated cells could be ascribable 
to a reduced activation of Akt, because this protein is 
responsible for the MDM2 phosphorylation [61–62]. On 
the other hand, it is likely that the reduced activation of 
Akt modulates the functions of other downstream proteins; 
under this concern, one possible candidate seems to be 
Bax, because of the increased levels of this pro-apoptotic 
factor observed upon treatment of A2058 with 7. In 
conclusion, we suggest that the early reduction of pAkt 
levels could be related to a concomitant impairment 
of CDC25 functions. In turn, the reduced activation of 
Akt could cause the deregulation of other downstream 
pathways leading to an increase of ROS level and later on 
of p53 levels.
Overall, our data indicate that the reduced 
viability of melanoma cells observed after treatment 
with compound 7 is probably related to the inhibition 
potency exhibited by this molecule on the CDC25 
phosphatase activity, as well as to the modulation of its 
protein levels among the different forms. Therefore, the 
deregulation of CDC25 in melanoma cells suggests that 
this crucial element of cell cycle could be considered 
as a possible oncotarget in vivo. Under this concern, it 
is known that advanced anti-melanoma strategies are 
based on the usage of BRAF inhibitors, that selectively 
inhibit the proliferation of melanoma cells harbouring 
the BRAFV600E mutation [56]. However, the success 
of this therapy is not definitive, because usually the 
patients relapse because of acquired drug resistance, 
possibly due to the activation of others survival 
pathways. An alternative strategy could be represented 
by the combination of two different drugs, co-targeting 
independent survival pathways that are critical for 
development and maintenance of melanoma. Hence, the 
study of the effects of CDC25 inhibitors in melanoma 
cells could be helpful for finding other molecular 
pathways, as possible targets for melanoma treatment. 
The present work represents the fruitful combination of 
computational and biochemical work. The identification 
of a variety of inhibitors containing a 6-xanthone 
chemical motif for CDC25 phosphatase targets was made 
without the need for a massive high-throughput chemical 
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screen. It is noteworthy that these tests were performed 
without the usage of robotics or highly automated 
methods, and the chemoinformatics and VS methods 
were performed on a common desktop computer. Thus, 
collaboration between (bio)chemical and VS provides 
an extraordinarily effective approach to drug discovery. 
A deeper insight in the molecular mechanisms of 7 in 
melanoma cells is under current investigation, in order 
to improve the structural and functional potency of this 
molecule; indeed, further refinement of this compound to 
higher affinity and more specific inhibition offers great 
therapeutic potential.
MATERIALS AND METHODS
Database: lead-like selection and preparation
The NCI Open Database (http://dtp.cancer.gov/) 
with 260.071 compounds was obtained from ZINC 
[39–40]. The compound database was processed with 
FILTER version 2.0.2 (OpenEye Scientific Software 
Inc., Santa Fe, USA, http://www.eyesopen.com/) to 
select a subset of lead-like compounds. We used the 
default parameters in the lead-like filter without further 
modifications. The resulting database, referred in this work 
as the NCI lead-like set, contained 65.375 compounds.
Chemoinformatic methods
All of the approaches below were performed in 
parallel against the full ZINC drug-like subset (~17.8 
million drug-like compounds) and the NCI lead-like set.
Molecular fingerprints
Five types of molecular FPs ECFP2, ECFP4, FCFP2, 
FCFP4, and FCFP6 [63] were calculated using Pipeline 
Pilot (Accelrys Inc., San Diego, USA, http://accelrys.
com/products/pipeline-Pilot/). Extended Connectivity 
Fingerprints (ECFPs) have been shown to have a number 
of strengths that make them useful for similarity searching. 
ECFPs are a FP methodology explicitly designed to 
capture molecular features relevant to molecular activity. 
They can be quickly calculated, as they are not defined 
a priori [63]. Functional Class Fingerprints (FCFPs) 
are a related fingerprint to ECFPs but instead of using a 
specific atom identifier for the initial atom in the algorithm 
to generate the fingerprint, FCFPs use a more abstract 
pharmacophoric set of initial atom identifiers based on 
properties such as H-bond acceptor (HBA) and donor 
(HBD), negatively and positively ionizable, aromatic, and 
halogen [63]. The similarity between the lead compound 
NSC 119915 and our compound libraries was assessed 
using the Tanimoto coefficient. The Tanimoto coefficient 
(Tc) is given by eq. 1:
 Tc(A,  B) =
c
a + b − c
 (1)
where a and b are the number of bits set in the fingerprints 
of molecules A and B, respectively, and c is the number 
of bits set in both fingerprints. The Tc ranges between 
0 and 1, with 0 corresponding to no fingerprint overlap 
and 1 to identical fingerprints. It should be noted that, 
identical fingerprints do not necessarily correspond to 
identical molecules (as fingerprints are only abstractions 
of molecular structures). Furthermore, as defined by 
the above formula, the Tc only takes into account bits 
set to 1 (i.e., features present in the molecule). Hence, 
the magnitude of the Tc value will be greatly influenced 
by the bit density in the underlying fingerprint, which 
on the other hand, increases with molecular size 
and complexity [64]. The calculation of Tc translates 
structural similarity into numerical values and can be 
interpreted as the “percentage of structural features 
shared between two compounds”, yet it is debatable 
which Tc value corresponds to “significant similarity”. 
There is no generally applicable Tc threshold for the 
indication of structural similarity, which is dependent on 
the molecular fingerprint applied [65]. In this work, we 
applied threshold values of 0.52, 0.43, 0.75, 0.60, 0.45 in 
combination with ECFP2, ECFP4, FCFP2, FCFP4, and 
FCFP6 fingerprints, respectively, because they give much 
higher confidence in correlating structural similarity [44].
Substructure search
ZINC drug-like and NCI lead-like collections 
were exposed to substructure 2D searching 
using as query the following SMILES notations: 
[O = c3ccc2cc1ccccc1oc2c3], [O = c3ccc2cc1ccccc1[nH]
c2c3] and [O = c3ccc2cc1ccccc1sc2c3]. Canvas version 
1.9 (Schrödinger, LLC, New York, USA) was used in this 
process by using SMILES Arbitrary Target Specification 
(SMARTS) filter module to carry out substructure search.
All structures retrieved from both molecular 
fingerprints and substructure search were combined 
and duplicates were removed, thus obtaining a single 
database of 126 unique compounds. Out of these 
compounds, we selected the top-ranked 25 compounds 
for CDC25 inhibitory assay.
Materials and reagents
All compounds were purchased from commercial 
vendors or kindly provided from the NCI/DTP. 
Compounds were dissolved in DMSO, and stock solutions 
at 10 mM concentration were prepared. Recombinant 
forms of the catalytic domains of CDC25A, -B and -C 
were obtained through the vectors pET28a-CDC25A-cd, 
pET28a-CDC25B-cd and pET28a-CDC25C-cd, kindly 
provided by H. Bhattacharjee (Florida International 
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University, Herbert Wertheim College of Medicine, Miami, 
Florida). Protein purification was obtained essentially 
as previously described [36]. The synthetic substrate for 
CDC25 phosphatase activity, OMFP, was purchased from 
Sigma-Aldrich. Dulbecco’s modified Eagle’s medium 
(DMEM), Roswell Park Memorial Institute (RPMI) 1640 
medium, fetal bovine serum (FBS), L-glutamine, penicillin 
G, streptomycin, and trypsin were purchased from Lonza 
(Milano, Italy). Propidium iodide (PI), dichlorofluorescein 
diacetate (DCFH-DA), Rhodamine 123 (R123), N-acetyl-
L-cysteine (NAC) and apocynin were purchased from 
Sigma-Aldrich. A protease inhibitor cocktail was obtained 
from Roche Diagnostics S.p.A. (Monza, Italy). Caspase-3 
and caspase-9 fluorimetric assay kits were purchased from 
BioVision (Milpitas, CA, USA). The pan-caspase inhibitor 
Z-VAD-FMK was purchased from Selleckchem (USA). 
Rabbit monoclonal antibody against glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) was obtained from 
Cell Signaling (Boston, MA, USA); mouse monoclonal 
antibody against CDC25A, CDC25C, or Bcl-2, rabbit 
polyclonal antibody against CDC25B, pAkt (Ser473) 
or Bax, and each secondary antibody conjugated to 
horseradish peroxidase were obtained from Santa 
Cruz Biotechnology (Heidelberg, Germany). All other 
chemicals were of analytical grade and were purchased 
from Sigma-Aldrich.
In vitro assays of CDC25 phosphatase activity
The enzymatic activity of the catalytic 
domains of CDC25A, -B and -C were determined 
through a fluorimetric method, which monitored the 
dephosphorylation of the synthetic substrate OMFP, 
essentially as previously described [36]. In steady-
state enzyme kinetic studies, the residual phosphatase 
activity of purified recombinant CDC25B was measured 
at 30°C in the presence of different concentrations of 
the various inhibitors, using a computer-assisted Cary 
Eclipse spectrofluorimeter (Varian) equipped with an 
electronic temperature controller. Excitation and emission 
wavelengths were set at 485 and 530 nm, respectively; 
both excitation and emission slits were set at 10 nm. The 
reaction mixture contained 10 nM CDC25B and different 
concentrations of the various inhibitors in 500 μL final 
volume of 20 mM Tris-HCl, pH 7.8, 1 mM DTT. DMSO 
was used as vehicle control. The reaction started by 
the addition of 25 μM OMFP, and the formation of the 
fluorescent product o-methylfluorescein was monitored 
continuously. The rate of OMFP hydrolysis was expressed 
as arbitrary units per min (a.u./min). The comparison of 
the rates determined in the absence and in the presence 
of the various inhibitors allowed the calculation of the 
residual phosphatase activity, expressed as a percentage.
To measure the inhibition constant (Ki) of the 
recombinant forms of CDC25A, -B and -C towards the 
various inhibitors, the affinity of the different forms 
of CDC25 towards OMFP was measured either in the 
absence or in the presence of fixed concentrations of the 
various inhibitors. The reaction mixture contained 20 nM 
CDC25A, or 10 nM CDC25B, or 40 nM CDC25C, 
and different concentrations of the various inhibitors in 
500 μL final volume of 20 mM Tris-HCl, pH 7.8, 1 mM 
DTT. DMSO was used as vehicle control. The reaction 
started by the addition of 1–25 μM OMFP, and the rate 
of OMFP hydrolysis was measured as indicated before. 
The corresponding Lineweaver-Burk plots allowed the 
calculation of the K
M
 for OMFP and of the V
max
 of OMFP 
hydrolysis, expressed as a.u./min
max
. In the presence of 
the various inhibitors the K
M
 value for OMFP remained 
essentially unchanged, whereas the V
max
 decreased, thus 
indicating that the selected compounds were noncompetitive 
inhibitors of CDC25. The Ki values were obtained from 
the decrease of a.u./min
max
 in the presence of the inhibitor, 
according to the equation a.u./mim
max
’ = a.u./mim
max
/{1 + 
([I]/Ki)}, where a.u./mimmax’  represents the Vmax measured 
in the presence of the concentration [I] of the inhibitor. The 
Ki values were obtained from at least three independent 
experiments and reported as mean ± S.E.
Cell culture
The human melanoma cell line A2058, kindly 
provided by CEINGE (Naples, Italy), and SAN cells [66] 
were derived from lymph nodal metastases and grown in 
DMEM and RPMI 1640, respectively, supplemented with 
10% FBS, 2 mM L-glutamine, 100 IU/mL penicillin G, and 
100 μg/mL streptomycin in humidified incubator at 37°C 
under 5% CO2 atmosphere. All cells were split and seeded 
every three days and used during the exponential phase of 
growth. Cell treatments were always carried after 24 h from 
plating.
3-(4,5-Dimethylthiazole-2-yl)-2,5-
biphenyltetrazolium bromide (MTT) assay
The MTT assay was used to detect cell proliferation 
essentially as previously described [67]. Briefly, A2058 
and SAN cells were plated in 96-well microtiter plates 
(100 μL/well) at 4000 and 6000 cells/well, respectively. 
After 24-h seeding, cells were treated with the selected 
compounds added at 25, 50 or 100 μM concentration, or 
with 0.5% (v/v) DMSO as a vehicle control. After 24-h, 
48-h or 72-h treatment, and upon the addition of 10 μL of 
MTT solution in the dark, the plate was incubated for 3 h 
at 37°C under CO2 atmosphere. After medium aspiration 
and solubilization of formazan crystals, absorbance was 
measured at 570 nm, using an ELISA plate reader (Bio-
Rad, Milano, Italy).
Cell cycle analysis and evaluation of apoptosis
Cells were seeded into 6-well plates at 3 × 105 cells/
well for 24 h at 37°C; after the addition of 100 μM 7 or 
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0.5% DMSO as a vehicle control, the incubation of treated 
cells continued for 16 or 24 h. After each treatment, cells 
were harvested with trypsin, centrifuged and the pellet 
was resuspended in phosphate-buffered saline (PBS). 
For cell cycle analysis, cells were fixed with 70% (v/v) 
cold ethanol and stored at –20°C for 1 h. Then, cells were 
washed with cold PBS, centrifuged and the pellets were 
resuspended in 200 μL of a non-lysis solution containing 
50 μg/mL PI. For the evaluation of apoptosis, cells were 
not fixed in ethanol and directly resuspended in 200 μL 
of a hypotonic lysis solution containing 50 μg/mL PI. 
After incubation at 4°C for 30 min, cells were analyzed 
with a FACScan flow cytometer (Becton Dickinson) for 
evaluating the distribution in cell cycle phases or the 
presence of nuclei with a DNA content lower than the 
diploid.
Measurements of caspase-3 and caspase-9 
activity
To estimate caspase-3 and caspase-9 activity 
during the treatment with compound 7, the respective 
enzymatic activities were measured by using caspase-3 
and -9 fluorimetric assay kits, according to the 
manufacturer’s protocol, essentially as previously 
described [68]. Briefly, cells were seeded into 75 cm2 
plates (2 × 106 cells/plate) for 24 h at 37°C and then 
treated with 100 μM 7 or 0.5% DMSO. At the end of 
each incubation, cells were collected, washed with 
PBS, and finally lysed at 4°C in the cell lysis buffer. 
Cell lysates were incubated with 50 μM DEVD-
AFC or LEHD-AFC substrates at 37°C for 2 h, 
to detect caspase-3 or caspase-9 activity, respectively, 
using a Cary Eclipse fluorescence spectrophotometer 
(Varian). Excitation and emission wavelengths were set 
at 400 nm and 505 nm, respectively; both excitation and 
emission slits were set at 10 nm.
Measurement of intracellular ROS content
The intracellular ROS level was monitored using the 
oxidation-sensitive fluorescence probe DCFH-DA. Cells 
were seeded into 6-well-plates (3 × 105 cells/plate) for 
24 h at 37°C and then treated at various times with 100 
μM compound 7 or 0.5% DMSO. DCFH-DA was added 
in the dark at 10 μM final concentration 30-min before 
the end of each incubation; then, cells were collected, 
washed in PBS, and finally resuspended in 500 μL PBS 
for fluorimetric analysis. Measurements were realized in 
a Cary Eclipse fluorescence spectrophotometer (Varian); 
excitation and emission wavelengths were set at 485 nm 
and 530 nm, respectively; both excitation and emission 
slits were set at 10 nm. The effect of 7 on ROS production 
was also estimated after pretreatment of cells with 10 mM 
NAC for 1 h.
Evaluation of mitochondrial membrane potential
Mitochondrial membrane potential was evaluated 
by measuring the incorporation of the fluorescent probe 
R123, essentially as previously described [69]. Briefly, 
cells were seeded into 6-well-plates (3 × 105 cells/well) 
for 24 h at 37°C, and then incubated at 37°C for 1 h in 
the presence of 5 μM R123, washed twice with PBS, and 
placed in medium containing 100 μM compound 7 or 
0.5% DMSO. After various times from treatment, cells 
were harvested, washed and centrifuged for 10 min at 4°C. 
The cellular pellet was resuspended in 500 μL PBS. The 
fluorescence of cell-associated R123 was detected in the 
above-mentioned fluorescence spectrophotometer, using 
excitation and emission wavelengths of 490 and 520 nm, 
respectively; both excitation and emission slits were set 
at 10 nm.
Western blotting
A2058 cells were seeded into 6-well-plates (3 × 105 
cells/plate) for 24 h at 37°C and then treated at different 
times with 100 μM compound 7 or 0.5% DMSO. After 
treatment, cells were harvested, washed with PBS and 
then lysed in ice-cold modified radio immunoprecipitation 
assay (RIPA) buffer (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 1% Nonidet P-40, 0.25% sodium deoxycholate, 
1 mM Na
3
VO
4
 and 1 mM NaF), supplemented with protease 
inhibitors and incubated for 30 min on ice. The supernatant 
obtained after centrifugation at 12,000 rpm for 30 min 
at 4°C constituted the total protein extract. The protein 
concentration was determined by the method of Bradford, 
using bovine serum albumin (BSA) as standard [70]. Equal 
amounts of total protein extracts were used for Western 
blot analysis. Briefly, protein samples were dissolved in 
SDS-reducing loading buffer, run on 12% SDS/PAGE and 
then transferred to Immobilon P membrane (Millipore). 
The filter was incubated with the specific primary antibody 
at 4°C overnight and then with the secondary antibody at 
room temperature for 1 h. Membranes were then analysed 
by an enhanced chemiluminescence reaction, using Super 
Signal West Pico kit (Pierce) according to manufacturer’s 
instruction; signals were visualized by autoradiography.
Statistical analysis
Data are reported as average and standard error. The 
statistical significance of differences among groups was 
evaluated using ANOVA, with the Bonferroni correction 
as post hoc test or the Student t test where appropriate. The 
significance was accepted at the level of p < 0.05.
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